Zum Inhalt springen
GLP-1 Newspaper: Daily Ozempic, Zepbound & Weight-Loss Drug News

GLP-1 Newspaper: Daily Ozempic, Zepbound & Weight-Loss Drug News

NeuNovo's CagriSema Cut Weight About 21% at Two Lower Doses in Phase 3 REDEFINE 9 Trial15.11.2026 · 7 Min.
Folgen
17
Erscheint
täglich
Letzte Folge
15. Nov. 2026

Über den Podcast

One GLP-1 story a day, sourced and explained. GLP-1 Newspaper covers the biggest daily news on weight-loss and diabetes drugs like Ozempic, Wegovy, Zepbound, Mounjaro, and new ones like retatrutide, orforglipron, and the Wegovy pill. Each short episode breaks down one story, such as an FDA decision, new trial results, price and insurance changes, shortages, or safety updates. We cover what happened, what it means for patients, and what we don't know yet. Every episode links to its primary sources, like FDA notices, clinical trial records, journals, and company announcements, at glp1newspaper.com.

For information only, not medical advice. Always talk to your doctor before starting, stopping, or changing any medication.

Lizenz: © 2026 GLP-1 Newspaper. All rights reserved.

Folgen 17

  1. Novo's CagriSema Cut Weight About 21% at Two Lower Doses in Phase 3 REDEFINE 9 Trial

    7 Min.

    Novo Nordisk reported full results from REDEFINE 9, the first Phase 3 weight-management trial of its investigational once-weekly injection CagriSema (a fixed-dose combination of the amylin analog cagrilintide …

  2. China Approves Lilly's Orforglipron Pill for Weight Management, the First Oral GLP-1 Cleared There for That Use

    3 Min.

    China's National Medical Products Administration has approved Eli Lilly's once-daily oral GLP-1 pill orforglipron, sold as Foundayo in the US and UK and as Muyouda in China, for long-term weight management …

  3. CDC Survey: About 1 in 10 U.S. Adults Used a GLP-1 in 2025, and 44% of Users Changed How They Took It

    5 Min.

    A new CDC report published November 12, 2026, in the Morbidity and Mortality Weekly Report looks at how U.S. adults used GLP-1 medications in 2025. In a national survey of 8,118 adults through CDC's Rapid …

  4. Boehringer's Survodutide Did Not Raise Heart Risk in a 5,530-Person Phase 3 Safety Trial, as Boehringer Moves Toward Obesity Filings

    5 Min.

    Boehringer Ingelheim's investigational weekly injection survodutide, a glucagon/GLP-1 dual agonist, did not increase the risk of major heart and blood-vessel events compared with placebo in the Phase 3 …

  5. Lilly's Foundayo Pill Reduced Sleep Apnea Severity in Two Phase 3 Trials, With an FDA Filing Planned by Year-End

    6 Min.

    Eli Lilly's once-daily GLP-1 pill Foundayo (orforglipron) reduced the severity of obstructive sleep apnea in its Phase 3 ATTAIN-OSA program, presented at the American Heart Association's Scientific Sessions …

  6. FDA Requires a Warning About Rare Vision Loss (NAION) on All GLP-1 Drugs, From Ozempic and Wegovy to Mounjaro and Zepbound

    7 Min.

    On November 9, 2026, the US Food and Drug Administration said it is requiring the makers of all GLP-1 receptor agonist medicines, including Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound and Foundayo, to add …

  7. Semaglutide Lowered Heart Filling Pressures in a Small Obesity-Related Heart Failure Trial, Plus New Tirzepatide MRI Data From SUMMIT

    7 Min.

    Two new sets of heart-failure data on GLP-1-based drugs were presented at the American Heart Association's Scientific Sessions 2026 in Chicago on November 8, 2026. In CAMEO-SEMA, a Mayo Clinic-led, double-blind …

  8. Novo Real-World Studies Link Wegovy to Lower Liver Enzymes and Weight in MASH, Presented at The Liver Meeting 2026

    9 Min.

    Novo Nordisk presented two real-world studies of Wegovy (semaglutide 2.4 mg) in adults with MASH at The Liver Meeting 2026 (AASLD) in Denver on November 6, 2026. In PLATINUM-Truveta, 2,873 adults who started …

  9. Lilly and Hims & Hers Offer Zepbound and Foundayo at Self-Pay Prices Starting at $149 and $299

    10 Min.

    Eli Lilly and Hims & Hers announced an agreement on November 6, 2026, to expand access to FDA-approved Zepbound (tirzepatide) and Foundayo (orforglipron) through the Hims & Hers telehealth platform. Eligible …

  10. Lilly Oral Orforglipron Beat Placebo on Weight Loss in Japan ATTAIN-J Phase 3, With 12 mg Leading Numerically

    18 Min.

    Eli Lilly's once-daily oral GLP-1 drug orforglipron reduced body weight more than placebo at 72 weeks in ATTAIN-J, a Japan-only Phase 3 trial in adults with obesity disease. Mean weight change was −5.9% at 6 …

  11. Lilly's Retatrutide Beat Ozempic 2 mg on Blood Sugar and Weight Loss in Head-to-Head Diabetes Trial

    16 Min.

    Eli Lilly says its investigational once-weekly drug retatrutide beat Novo Nordisk's Ozempic 2 mg in TRANSCEND-T2D-2, the first Phase 3 trial comparing retatrutide head-to-head with another incretin medicine. We …

  12. Lilly Registers Two Phase 3 Trials of EloraTZP, Its Eloralintide-Tirzepatide Combination

    6 Min.

    Eli Lilly has registered two phase 3 trials of EloraTZP, an investigational once-weekly combination of the amylin agonist eloralintide and tirzepatide (the active ingredient in Zepbound and Mounjaro), on …

  13. Lilly's Retatrutide Eased Sleep Apnea in Two Phase 3 Trials, NEJM Study Reports

    13 Min.

    Two phase 3 trials published in the New England Journal of Medicine found that Eli Lilly's investigational drug retatrutide, a once-weekly injection that acts on GIP, GLP-1 and glucagon receptors, reduced the …

  14. ACOG Issues New Guidance on GLP-1 Drugs Before Pregnancy, During Pregnancy and While Breastfeeding

    9 Min.

    The American College of Obstetricians and Gynecologists (ACOG) released new guidance on October 23, 2026, on GLP-1 medications before, during and after pregnancy. The Practice Advisory tells ob-gyns to advise …

  15. Compounded GLP-1 Recall and 'Research Use' Retatrutide Put Unapproved Weight-Loss Drugs Under Scrutiny

    22 Min.

    Unapproved GLP-1 drugs are under pressure from several directions. Compounding pharmacy Apothecary Pharma voluntarily recalled 22 lots of compounded tirzepatide, the active ingredient in Zepbound and Mounjaro …

  16. EU Regulators Back Lilly's Foundayo Pill for Weight Loss and Type 2 Diabetes

    11 Min.

    Europe's drug regulator has recommended approval of Eli Lilly's once-daily GLP-1 pill Foundayo (orforglipron) for adults, covering both weight management and type 2 diabetes. The European Medicines Agency's …

  17. Novo Says Women Lost 25% on CagriSema in Trial Analysis, With Differences by Menopause Stage

    15 Min.

    Novo Nordisk says women in its phase 3 REDEFINE 1 trial lost 25.0% of their body weight on average after 68 weeks on its investigational weekly injection CagriSema (cagrilintide plus semaglutide), compared with …

Ist das dein Podcast?

Bestätige es mit einem Eintrag in deinem Feed: Du bekommst hier einen Code, trägst ihn als podcast:txt in den Kanal deines Feeds ein, und wir prüfen ihn. Danach steht dein Podcast als „verifiziert“ bei SoundNode.

Einstellungen

Darstellung

Sprache

Bestimmt, welche Sender dir auf der Startseite zuerst gezeigt werden.

Verlauf

Zuletzt gehörte Sender und Folgen und deine letzten Suchen liegen nur in diesem Browser.

Hinweise

Ein kurzer Hinweis, wenn ein Podcast, dem du folgst, eine neue Folge hat. Einzelne Podcasts stellst du über die Glocke auf ihrer Seite ab.

Konto

Favoriten speichern – in der App und auf der Website.

Tastenkürzel

/
Suche öffnen
Leertaste
Abspielen oder anhalten
← →
Im Player: 15 s zurück, 30 s vor (Folgen) · im Regal: nächste Kachel
↑ ↓
Im Regal: Ziel innerhalb der Kachel
Pos1 / Ende
Im Regal: erste bzw. letzte Kachel
Esc
Fenster oder Menü schließen
?
Diese Übersicht
Läuft gerade

Zur Senderseite

Als Nächstes

    Folgen mit „Als Nächstes“ vormerken – sie laufen nach der aktuellen Folge.